Response to SARS‐CoV‐2 vaccination and antibodies persistence in multiple myeloma patients

N/A This article is protected by copyright. All rights reserved.

Saved in:
Bibliographic Details
Published inHematological oncology Vol. 41; no. 1; pp. 210 - 212
Main Authors Pettine, Loredana, Bortolotti, Marta, Fattizzo, Bruno, Da Vià, Matteo C., Consonni, Dario, Pompa, Alessandra, Bolli, Niccolò, Baldini, Luca
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.02.2023
John Wiley and Sons Inc
Subjects
Antibodies
COVID-19 - prevention & control
COVID-19 Vaccines
Humans
Letter to the Editor
Multiple myeloma
Multiple Myeloma - therapy
response to vaccination
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Vaccination
response to vaccination
SARS-CoV-2
multiple myeloma
Online AccessGet full text

Cover

More Information
Summary:N/A This article is protected by copyright. All rights reserved.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/hon.3051
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.3051